Drugmakers Show Restraint on Price Increases in New Trump Era
The companies raised prices a median 4%, though some drugs will cost thousands of dollars more.
ENDPOINTS NEWS12h
Semaglu­tide, tirzepatide com­pounder hit with FDA warn­ing let­ter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
Ozempic vs. Semaglutide: 10 Weight Loss Medications Compared for 2025
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
Palatin Provides Update On Anticipated 2025 Corporate Milestones
Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...
The Meadville Tribune20h
Ozempic, anti-diabetic drugs spike in popularity
The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...
LEXX: IRB Approval Clears Way for GLP-1 Study #5
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital ...